Granules India Stock Hits ₹640, Nears 52-Week High

Granules India Reaches New Peak

Granules India's stock has demonstrated significant strength, hitting a new 52-week high in recent trading sessions. The pharmaceutical company's share price touched ₹640, surpassing its previous high of ₹621.10 recorded on January 7, 2025. This upward momentum is part of a broader market rally that has seen the BSE Sensex gain substantially. The stock's performance has captured investor attention, outperforming both the benchmark index and its sectoral peers over the past month. This surge reflects growing confidence in the company's strategic direction and operational capabilities.

A Closer Look at Stock Performance

In the last month alone, Granules India's stock has surged by approximately 18%, a stark contrast to the BSE Sensex's 0.85% rise and the BSE Healthcare index's 0.27% decline during the same period. This outperformance highlights the specific positive catalysts driving the company's valuation. The stock has made a remarkable recovery, bouncing back by 45% from its low of ₹433 in August. This sustained rally indicates strong underlying fundamentals and positive market sentiment, positioning Granules India as a notable performer in the pharmaceutical space.

Strategic Fundraising for Future Growth

A key factor fueling the stock's ascent is the company's ambitious fundraising plan. The board has approved raising a total of ₹1762.5 crore. This includes ₹1462.5 crore through the issuance of 25 million convertible warrants to both promoter and non-promoter groups, payable within 18 months. An additional ₹300 crore will be raised by issuing 5.1 million equity shares on a preferential basis to non-promoter investors. These funds are expected to be allocated towards the company's expansion into high-growth segments, including Oncology and GLP-1 peptides, signaling a clear strategy for future value creation.

Positive Regulatory Developments

Granules India has also benefited from a series of positive regulatory updates from the United States Food and Drug Administration (USFDA). Its wholly-owned subsidiary, Granules Pharmaceuticals Inc., received tentative approval for its Abbreviated New Drug Application (ANDA) for Amphetamine extended-release tablets, a medication used for attention deficit hyperactivity disorder (ADHD). Furthermore, another subsidiary, Granules Life Sciences, received a successful Establishment Inspection Report (EIR) for its Hyderabad facility, confirming its compliance with stringent quality standards. These approvals are crucial for expanding the company's product portfolio and market access in the US.

Strong Financials Underpinning the Rally

The company's solid financial performance provides a strong foundation for its market rally. In its third-quarter results, Granules India reported a 28% year-on-year increase in Profit After Tax (PAT), which stood at ₹150 crore. The Profit Before Tax (PBT) also saw a significant jump of 32.36% to ₹202.23 crore. This growth was primarily driven by the Finished Dosages segment in key markets like North America and Europe. These robust earnings demonstrate the company's ability to execute its strategy effectively and generate value for its stakeholders.

Analyst Viewpoint and Price Targets

Market analysts have taken note of these positive developments. Choice Institutional Equities, for instance, maintains a positive outlook on the company, citing its strong execution capabilities and the expected operational ramp-up at its facilities. The brokerage firm has revised its earnings estimates upward for FY26 and FY27 and increased its target price for the stock to ₹660 from a previous ₹640. However, due to the recent sharp increase in the stock price, the firm has revised its rating from 'BUY' to 'ADD', suggesting that while the outlook is positive, much of the near-term upside may already be priced in.

Pharma Sector's Broader Recovery

Granules India's performance is also part of a wider recovery in the Indian pharmaceutical sector, which has seen a significant rebound since April 2025. Several major pharma companies have posted strong gains, driven by factors like supportive US policies, strong exports, and improved margins. This renewed investor confidence has made the pharmaceutical sector one of the top-performing areas of the market.

Future Outlook and Long-Term Drivers

Looking ahead, Granules India's growth is expected to be driven by several factors. The clearance of its Gagillapur facility, anticipated by January 2026, is expected to boost operations. Over the longer term, new product launches within its contract development and manufacturing organization (CDMO) and peptides divisions are projected to become significant revenue contributors from FY27 onwards. These strategic initiatives, combined with consistent regulatory compliance and R&D investments, paint a promising picture for the company's future.

Disclaimer: This article is for informational purposes only and should not be considered as investment advice. Stock market investments are subject to market risks. Please consult with a financial expert before making any investment decisions.